Reaction Details Report a problem with these data
Target
IgG receptor FcRn large subunit p51
Ligand
BDBM50270833
Substrate
n/a
Meas. Tech.
ChEMBL_552584 (CHEMBL956456)
IC50
>125000±n/a nM
Citation
 Mezo, AR; McDonnell, KA; Castro, A; Fraley, C Structure-activity relationships of a peptide inhibitor of the human FcRn:human IgG interaction. Bioorg Med Chem 16:6394-405 (2008) [PubMed]  Article 
Target
Name:
IgG receptor FcRn large subunit p51
Synonyms:
FCGRN_HUMAN | FCGRT | FCRN
Type:
PROTEIN
Mol. Mass.:
39742.86
Organism:
Homo sapiens (Human)
Description:
ChEMBL_627631
Residue:
365
Sequence:
MGVPRPQPWALGLLLFLLPGSLGAESHLSLLYHLTAVSSPAPGTPAFWVSGWLGPQQYLSYNSLRGEAEPCGAWVWENQVSWYWEKETTDLRIKEKLFLEAFKALGGKGPYTLQGLLGCELGPDNTSVPTAKFALNGEEFMNFDLKQGTWGGDWPEALAISQRWQQQDKAANKELTFLLFSCPHRLREHLERGRGNLEWKEPPSMRLKARPSSPGFSVLTCSAFSFYPPELQLRFLRNGLAAGTGQGDFGPNSDGSFHASSSLTVKSGDEHHYCCIVQHAGLAQPLRVELESPAKSSVLVVGIVIGVLLLTAAAVGGALLWRRMRSGLPAPWISLRGDDTGVLLPTPGEAQDADLKDVNVIPATA
  
Inhibitor
Name:
BDBM50270833
Synonyms:
(2S)-1-{2-[(2S)-2-[(2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-(2-{2-[(2S)-2-[(2S)-2-[(2R)-2-[(2S,3R)-2-[(2R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-sulfanylpropanamido]-3-hydroxybutanamido]propanamido]-3-(1H-imidazol-5-yl)propanamido]-3-phenylpropanamido]acetamido}acetamido)-4-methylpentanamido]-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]formamido}-3-sulfanylpropanamido]-3-carbamoylpropanamido]acetyl}pyrrolidine-2-carboxylic acid | CHEMBL500533
Type:
Small organic molecule
Emp. Form.:
C83H118N24O22S2
Mol. Mass.:
1868.103
SMILES:
CC(C)C[C@H](NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](C)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O |r,wU:87.89,102.107,127.133,37.39,74.77,27.35,52.62,4.4,42.44,112.116,81.85,wD:63.73,16.24,46.50,106.110,(30.84,3.22,;30.84,1.69,;32.18,.92,;29.5,.92,;29.5,-.6,;28.17,-1.39,;26.84,-.62,;26.84,.91,;25.51,-1.38,;24.18,-.6,;22.85,-1.37,;22.85,-2.91,;21.51,-.59,;20.18,-1.37,;18.84,-.6,;18.84,.93,;17.53,-1.36,;17.53,-2.91,;18.84,-3.68,;20.17,-2.92,;21.5,-3.7,;21.49,-5.24,;20.15,-6,;18.83,-5.23,;16.18,-.61,;14.85,-1.38,;14.85,-2.93,;13.5,-.6,;13.5,.93,;14.85,1.7,;16.26,1.05,;17.29,2.19,;16.53,3.53,;15.02,3.23,;12.17,-1.37,;10.83,-.62,;10.83,.91,;9.51,-1.38,;9.51,-2.92,;8.17,-.61,;6.84,-1.38,;6.84,-2.93,;5.5,-.6,;4.17,-1.37,;2.82,-.61,;2.82,.91,;1.51,-1.37,;1.51,-2.93,;2.82,-3.69,;.18,-.59,;-1.15,-1.37,;-1.15,-2.93,;-2.49,-.6,;-2.49,.93,;-1.15,1.71,;.2,.92,;1.53,1.68,;1.53,3.21,;.2,3.99,;-1.13,3.23,;-3.84,-1.34,;-5.19,-.6,;-5.19,.92,;-6.52,-1.37,;-6.52,-2.91,;-5.19,-3.68,;-5.19,-5.22,;-3.84,-5.95,;-3.86,-7.49,;-5.2,-8.25,;-2.53,-8.25,;-7.82,-.54,;-9.14,-1.33,;-9.14,-2.87,;-10.47,-.56,;-11.77,-1.27,;-10.47,.98,;-9.12,1.75,;-9.12,3.28,;-10.42,4.05,;-7.78,4.06,;5.5,.93,;4.18,1.69,;6.85,1.7,;30.84,-1.38,;30.84,-2.93,;32.16,-.62,;33.5,-1.39,;34.82,-.63,;34.82,.89,;33.51,1.66,;33.51,3.21,;34.86,3.97,;34.87,5.49,;36.18,3.19,;36.17,1.65,;33.5,-2.95,;32.16,-3.72,;34.82,-3.71,;36.4,-3.16,;37.42,-4.49,;36.48,-5.88,;35.08,-5.2,;33.85,-6.12,;32.47,-5.45,;33.98,-7.66,;32.7,-8.51,;31.31,-7.83,;30.04,-8.7,;32.81,-10.04,;34.18,-10.71,;31.54,-10.91,;31.64,-12.45,;33.02,-13.13,;33.12,-14.66,;31.86,-15.53,;34.51,-15.33,;30.36,-13.31,;28.98,-12.64,;30.48,-14.85,;29.2,-15.7,;29.3,-17.23,;30.68,-17.91,;28.02,-18.1,;27.84,-19.76,;26.2,-20.1,;25.36,-18.66,;26.58,-17.69,;26.27,-16.18,;24.82,-15.69,;27.43,-15.16,)|
Structure:
Search PDB for entries with ligand similarity: